Cutler Group LP Apellis Pharmaceuticals, Inc. Put Options Transaction History

Cutler Group LP

15 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 Apr 19, 2024	SELL	$55.39 - $72.47 $1.2 Million - $1.57 Million	-21,700 Reduced 79.78%	5,500 $27,000
Q4 2023 Jan 18, 2024	SELL	$37.14 - $64.82 $1.75 Million - $3.06 Million	-47,200 Reduced 63.44%	27,200 $52,000
Q3 2023 Nov 07, 2023	BUY	$23.65 - $89.22 $1.39 Million - $5.25 Million	58,800 Added 376.92%	74,400 $436,000
Q2 2023 Jul 18, 2023	SELL	$76.68 - $93.31 $76,680 - $93,310	-1,000 Reduced 6.02%	15,600 $33,000
Q1 2023 May 01, 2023	SELL	$46.59 - $66.96 $568,398 - $816,911	-12,200 Reduced 42.36%	16,600 $42,000
Q4 2022 Feb 07, 2023	BUY	$43.24 - $61.04 $350,244 - $494,424	8,100 Added 39.13%	28,800 $242,000
Q3 2022 Oct 25, 2022	BUY	$44.76 - $69.66 $268,560 - $417,960	6,000 Added 40.82%	20,700 $139,000
Q2 2022 Aug 04, 2022	BUY	$35.07 - $59.21 $322,644 - $544,732	9,200 Added 167.27%	14,700 $324,000
Q1 2022 Apr 14, 2022	SELL	$35.46 - $54.12 $6.13 Million - $9.35 Million	-172,800 Reduced 96.92%	5,500 $102,000
Q3 2021 Oct 26, 2021	BUY	$31.4 - $69.84 $5.44 Million - $12.1 Million	173,400 Added 3538.78%	178,300 $732,000
Q2 2021 Jul 19, 2021	SELL	$40.9 - $64.9 $4,090 - $6,490	-100 Reduced 2.0%	4,900 $8,000
Q2 2020 Jul 22, 2020	SELL	$24.8 - $38.49 $183,520 - $284,826	-7,400 Reduced 59.68%	5,000 $8,000
Q1 2020 May 07, 2020	SELL	$17.91 - $44.33 $8,955 - $22,165	-500 Reduced 3.88%	12,400 $61,000
Q4 2019 Feb 06, 2020	BUY	$22.1 - $30.8 $280,670 - $391,160	12,700 Added 6350.0%	12,900 $51,000
Q3 2019 Oct 28, 2019	BUY	$24.09 - $32.18 $4,818 - $6,436	200 New	200 $0

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.